Integrated Neuroimaging, Department of Psychiatry, Trinity College, Dublin, Ireland.
J Clin Psychiatry. 2011 Apr;72(4):448-57. doi: 10.4088/JCP.09m05393blu. Epub 2010 Sep 21.
Antidepressants with different mechanisms of action might have different effects on brain functions. The aim of the study was therefore to investigate effects of 2 antidepressants on brain activation and to identify predictors for therapy response.
Twenty-four untreated patients with major depressive disorder (according to Structured Clinical Interview for DSM-IV) were enrolled in a prospective, randomized, 4-week trial with mirtazapine and venlafaxine. Functional magnetic resonance imaging (fMRI) was performed at baseline and after 4 weeks in the patients and in 15 healthy controls. The primary outcome measure was fMRI blood-oxygen-level dependence (BOLD) activation. The patients were recruited in 2007 and 2008.
Comparison between patients and controls revealed that emotional face matching elicited enhanced activation in the anterior cingulate cortex (ACC), dorsomedial prefrontal cortex, dorsolateral prefrontal cortex, and basal ganglia in patients. During treatment, a significant decrease of BOLD responses was seen in the hippocampus, basal ganglia, thalamus, and cerebellum of venlafaxine-treated patients, and a significant increase in BOLD responses was seen in the middle cingulate gyrus and supplementary motor area of mirtazapine-treated patients (P < .05, family wise error [FWE] cluster-level corrected). Larger BOLD responses in the left fusiform gyrus at baseline predicted a better response to venlafaxine, and smaller BOLD responses in the right rolandic operculum at baseline predicted a better response to mirtazapine (P < .05, FWE cluster-level corrected).
These fMRI results indicate that antidepressants with different mechanisms of action have different effects on brain function. It therefore seems that fMRI can be used for therapy evaluation and response prediction and can facilitate the development of new pharmaceuticals.
具有不同作用机制的抗抑郁药可能对大脑功能产生不同的影响。因此,本研究旨在探讨两种抗抑郁药对大脑激活的影响,并确定治疗反应的预测因子。
24 名未经治疗的重性抑郁症患者(根据 DSM-IV 结构临床访谈)被纳入一项前瞻性、随机、为期 4 周的米氮平和文拉法辛试验。在患者和 15 名健康对照者中,在基线和 4 周后进行功能磁共振成像(fMRI)。主要的测量指标是 fMRI 血氧水平依赖(BOLD)激活。患者于 2007 年和 2008 年招募。
与对照组相比,患者的情绪面孔匹配引起前扣带皮层(ACC)、背内侧前额叶皮层、背外侧前额叶皮层和基底节的激活增强。在治疗期间,文拉法辛治疗的患者的海马体、基底节、丘脑和小脑的 BOLD 反应明显下降,米氮平治疗的患者的中扣带回和辅助运动区的 BOLD 反应明显增加(P <.05,经 FWE 集群水平校正)。基线时左侧梭状回的 BOLD 反应越大,预示着对文拉法辛的反应越好,而基线时右侧 Rolandic 脑回的 BOLD 反应越小,预示着对米氮平的反应越好(P <.05,经 FWE 集群水平校正)。
这些 fMRI 结果表明,具有不同作用机制的抗抑郁药对大脑功能有不同的影响。因此,fMRI 似乎可用于治疗评估和反应预测,并能促进新药的开发。